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Mast cells and basophils, which are derived 
from hematopoietic progenitor cells, are key 
eff   ector cells in IgE-mediated immune re-
sponses, such as allergy and host protection 
against parasites (1–4). Upon binding of the an-
tigen to IgE, these eff  ector cells immediately 
release various proinfl  ammatory molecules, in-
cluding chemical mediators and cytokines (1–4). 
These cells express high affi   nity FcR for IgE 
(FcεRI), which is composed of an IgE-binding 
α subunit, a β subunit (FcεRIβ), and a disul-
phide-bonded γ subunit (FcRγ) homodimer 
(4, 5). Both FcRγ and FcεRIβ contain a cyto-
plasmic amino acid sequence termed immuno-
receptor tyrosine–based activation motif (ITAM) 
(4, 5). Upon clustering of FcεRI by IgE and 
multivalent antigens, the intracellular Src family 
protein tyrosine kinases phosphorylate tyrosine 
residues of the ITAMs of FcRγ and FcεRIβ 
(4, 5). The phosphorylated ITAM serves as the 
binding site for Syk, resulting in its activation 
and autophosphorylation, which leads to the 
induction of a further downstream signaling 
cascade (4). Mast cells and basophils also ex-
press other ITAM-bearing receptors, such as 
type III low affi   nity FcR for IgG (FcγRIII), 
and many activating-type receptors, including 
Toll-like receptors, as well as those for comple-
ment components like cytokines and chemo-
kines (2, 3). These receptors can also activate 
mast cells or basophils upon binding to their 
cognate ligands, resulting in the de novo syn-
thesis and release of cytokines, chemokines, 
and lipid mediators (1–4). Upon stimulation by 
these activating receptors, mast cells or baso-
phils are triggered within a few minutes, thus 
leading to acute hypersensitive responses, such 
as anaphylaxis and acute asthma attack (4). 
Moreover, the constitutive binding of mono-
meric IgE molecules to FcεRI can amplify 
cell-surface expression of FcεRI and its sig-
naling (1, 4, 6).
Considering the presence of diff  erent ways 
to stimulate mast cell or basophil activation cas-
cades, one may predict the importance of the 
counterregulatory system of mast cells or baso-
phils, which tightly suppress any spontaneous 
or excessive activation of the cells. In fact, like 
other cells in the immune system, mast cells 
and basophils express various inhibitory recep-
tors, which counteract activating receptors 
on the same cells (7). In mice, these include 
FcγRIIB (7, 8), mast cell function–associated 
antigen (9), and gp49B (10), all of which   harbor 
one or more immunoreceptor tyrosine–based 
inhibitory motifs (ITIMs) in their cytoplasmic 
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portions. When coengaged with activating-type receptors 
such as FcεRI, the tyrosine residues in these ITIMs of the 
  inhibitory receptors are phosphorylated (1, 7) and recruit 
Src homology domain 2–containing inositol polyphosphate 
5′-phosphatase (1, 7) or Src homology domain 2–containing 
tyrosine phosphate (SHP)–1 (1, 7), both of which dephos-
phorylate the ITAM-induced signaling molecules. There-
fore, mast cells lacking these inhibitory receptors are sensitive 
to IgE stimulation (7). In contrast, mast cells lacking acti-
vating receptors show attenuated responses to various stim-
ulation, indicating that the mast cell activation is regulated 
by adequate balancing between activating and inhibitory 
receptors (1–4, 7).
Leukocyte Ig-like receptors (LILRs) are a family of Ig-
like receptors encoded by several genes and are expressed on 
various immune cells, such as those of myeloid and lymphoid 
lineages (11, 12). LILRs are divided into two types of receptors: 
activating-type receptors (LILRA1–A6) and inhibitory-type 
receptors (LILRB1–B5). Activating-type LILRs, which as-
sociate with FcRγ, deliver positive signals into the cells, 
whereas inhibitory-type LILRs harbor ITIMs in their cyto-
plasmic portions and deliver inhibitory signaling by re-
cruiting SHP-1 to the phosphotyrosylated ITIMs (11, 12). 
Although it remains unclear whether LILRs are expressed on 
mast cells, peripheral basophils express several LILRs, such as 
LILRA2, LILRB2, and LILRB3 proteins (13). Recent stud-
ies demonstrated that LILRA2 can elicit eff  ector functions of 
basophils upon cross-linking with antibodies (13). Moreover, 
LILRB2 represses the basophil activation stimulated with 
IgE or anti-LILRA2 (13), showing that LILRs have an es-
sential role in the function of basophils. Although a full 
spectrum of the ligands for LILRs is not yet clarifi  ed, several 
LILRs are found to recognize MHC class I molecules as their 
ligands (12, 14). In particular, LILRB1 and LILRB2 can bind 
various classical or nonclassical MHC class I without allele 
specifi  city (14).
Mouse LILR relatives or orthologues, paired Ig-like re-
ceptors (PIRs) (15, 16) are also composed of two isoforms, 
activating PIR-A and inhibitory PIR-B, expressed on vari-
ous hematopoietic cell lineages, including B cells, mast cells, 
macrophages, granulocytes, and DCs, but are not expressed 
on T cells and NK cells (16, 17). PIR-A requires ITAM-
containing FcRγ for its cell-surface expression and signal 
transduction (17–21). In contrast, PIR-B contains ITIMs in 
its cytoplasmic portion and inhibits activation signaling upon 
coengagement with other activating receptors (20, 22, 23). 
Indeed, artifi   cial cross-linking of PIR-B to FcεRI-bound 
IgE with antibodies suppressed the IgE-mediated calcium re-
sponse and degranulation of mast cells, suggesting that PIR-B 
can suppress FcεRI-mediated mast cell signaling (24).
Recently, we found that PIR-B, as well as PIR-A, can 
bind MHC class I molecules (25). Like LILRB1 and LILRB2 
proteins, the recombinant PIR-B had similar binding af-
fi  nities to various mouse MHC class I proteins. Therefore, 
the identifi  cation of the ubiquitously expressed “self” marker 
proteins as the ligands for PIRs and LILRs raises the possibility 
of whether cells expressing PIRs or LILRs, such as mast cells 
and basophils, could be autoregulated by the MHC class I mol-
ecules expressed on their own (in cis) or influenced by 
the self-marker molecules on the surrounding cells (in trans), 
or both. Clarifying this question should be fundamentally im-
portant, because it will provide us with an invaluable notion 
of the mode of regulation in MHC class I and its receptors, 
which probably constitute pivotal components maintaining 
peripheral tolerance. As predicted by the missing-self hy-
pothesis (26), various inhibitory receptors for MHC class I 
molecules have been identifi  ed in NK cells and T cell subsets 
(27–29), such as killer Ig-like receptors (30), CD94/NKG2A 
heterodimers (31), and the C-type lectin superfamily, includ-
ing mouse Ly49 receptors (32). In the NK cell case, trans 
regulation has been verifi  ed to be important, because MHC 
class I on surrounding cells is monitored through their inhibi-
tory MHC class I receptors that suppress NK cell–mediated 
cytotoxicity against class I–bearing normal cells and target ab-
normal cells that do not suffi   ciently express MHC class I, 
such as virus-infected cells (27, 29). Recent analysis on mouse 
Ly49A suggested the consequences of both cis and trans inter-
actions between Ly49A and its ligand H-2Dd for the optimal 
regulation of NK cells (33). However, little is known about 
the mode of regulation for other MHC class I–recognizing 
receptors such as LILRs on other immune cells, including 
basophils. In particular, mechanisms of PIRs and the MHC 
class I binding in mast cell regulation remain to be clarifi  ed, 
although the possible signifi  cance of PIR-B in allergic reac-
tions has been suggested, because Th2 cell–skewed immune 
responses, in terms of increased IL-4 production and enhanced 
IgG1 and IgE production, were seen in PIR-B–defi  cient 
(Pirb−/−) mice in response to immunization with thymus-
dependent antigens (34).
In this paper, we demonstrate the physiologic importance 
of constitutive cis association between LILRB2 or PIR-B 
and MHC class I on human basophilic cell lines or mouse 
mast cells, respectively. In particular, mast cells from either 
Pirb−/− mice or MHC class I–defi  cient  β2-microglobulin 
(β2m)–defi  cient (B2m−/−) mice and these animals themselves 
revealed similar profi  les upon stimulation, namely IgE- and 
FcεRI-mediated degranulation, cytokine and lipid mediator 
release, and systemic anaphylaxis. These results show the es-
sential role of the self-recognizing PIR-B or LILRB2 system 
in the suppression of allergic responses.
RESULTS
Cis association between LILRB2 and MHC class I
We initially examined cell-surface expression of inhibitory 
LILRs on human basophilic KU812 cells by fl  ow cytometry. 
Consistent with the published data of human peripheral 
  basophils (13), KU812 cells express LILRB2 and LILRB3 
but not LILRB1 and LILRB4 (Fig. 1 A). KU812 cells also 
express substantial levels of FcεRI, HLA-A, B, C, and β2m 
(Fig. 1 B).
LILRB2s are known to recognize a broad range of classi-
cal MHC class I molecules and nonclassical MHC class I JEM VOL. 204, April 16, 2007  909
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molecules, such as HLA-G (14). However, the cell-surface lo-
calization of LILRB2 and MHC class I remains to be clarifi  ed. 
Therefore, we next investigated LILRB2 and HLA-A, 
B, C expression on KU812 cells by confocal microscopy. 
LILRB2 was clearly colocalized within a pixel ( 20 nm) 
with HLA-A, B, C on the same cell surface as KU812 
cells (Fig. 1 B). On the other hand, unlike LILRB2, LILRB3 
does not bind MHC class I (14); thus, we used it as the 
Figure 1.  Expression of LILRs on KU812 cells. (A) Flow cytometric 
analysis of cell-surface expression on KU812 cells stained with mAb 
against FcεRI (CRA1), HLA-A, B, C (G46-2.6), β2m (TÜ99), LILRB1 (GHI/75), 
LILRB2 (287219), LILRB3 (222821), and LILRB4 (ZM3.8). (B) Confocal imag-
ing of KU812 cells. KU812 cells were stained with (top) Alexa Fluor 546–
conjugated anti-LILRB2 (287219) and Alexa Fluor 647–conjugated 
anti–HLA-A, B, C (G46-2,6), (middle) Alexa Fluor 546–conjugated anti-
LILRB3 (222821) and Alexa Fluor 647–conjugated anti–HLA-A, B, C, and 
(bottom) Alexa Fluor 546–conjugated anti-β2m (TÜ99) and Alexa Fluor 
647–conjugated anti–HLA-A, B, C. DIC, differential interference contrast. 
(C) The fl  uorescence profi  le histogram for each image demonstrated the 
relative fl  uorescence intensity in each pixel (y axis) along the linearized 
cell surface (x axis). (D) Correlation coeffi  cients calculated for colocaliza-
tion of LILRB2, LILRB3, β2m, and HLA-A, B, C in KU812 cells are shown 
(n = 15). Data are shown as mean ± SD.910  CIS BINDING OF INHIBITORY RECEPTORS TO MHC CLASS I REGULATES ALLERGY | Masuda et al.
negative control. Indeed, LILRB3 did not overlap with HLA-
A, B, C (Fig. 1 B). To further quantitatively confi  rm the 
colocalization between LILRB2 and HLA-A, B, C, the fl  uores-
cence intensity values were measured. As shown in Fig. 1 C, 
illustrating the linearized fl  uorescence intensity profi  les, the 
colocalization between LILRB2 and HLA-A, B, C was much 
more substantial than that between LILRB3 and HLA-A, B, C. 
In addition, the correlation coeffi   cient (σx,y) was calculated 
for the intensity between LILRB2 or LILRB3 and HLA-A, 
B, C. The σx,y between LILRB2 and HLA-A, B, C (σx,y = 
0.407 ± 0.121) was considerably higher than that between 
LILRB3 and HLA-A, B, C (σx,y = 0.097 ± 0.175; Fig. 1 D). 
As a positive control, β2m was colocalized well with HLA-A, 
B, C (σx,y = 0.688 ± 0.163; Fig. 1, B–D). These results sug-
gested that LILRB2 can bind MHC class I on the same cell 
surface in cis.
To confi   rm the cis association between LILRB2 and 
MHC class I on KU812 cells, we also performed fl  uorescence 
resonance energy transfer (FRET) analysis by confocal laser 
microscopy with Alexa Fluor 546–conjugated anti-LILRB2 
mAb as an energy donor and Alexa Fluor 647–conjugated 
anti-HLA-A, B, C mAb as an acceptor, because the effi   ciency 
of the FRET from donor to acceptor represents a very sensi-
tive indicator of the molecular colocalization on a scale of 
2–10 nm (Fig. 2) (35). Table I summarizes the FRET effi   -
ciencies between donors and acceptors obtained by the con-
focal laser microscopy. When KU812 cells were doubly stained 
with Alexa Fluor 546–conjugated LILRB2 mAb (green) 
and Alexa Fluor 647–conjugated HLA-A, B, C mAb (red) 
and then excited with the 543-nm laser, we detected a strong 
FRET eff  ect from the excited LILRB2 mAb signal to the 
HLA-A, B, C mAb signal (20.7 ± 3%; Fig. 2 and Table I). 
As a positive control, β2m showed a strong energy transfer 
with HLA-A, B, C (14.5 ± 4.7%; Fig. 2 and Table I). In 
contrast, negative control LILRB3 did not show a notable 
energy transfer with HLA-A, B, C on KU812 cells (4 ± 
4.9%; Fig. 2 and Table I). These fi  ndings demonstrate that 
LILRB2 can associate with MHC class I in cis.
Cis association between PIR-B and MHC class I
To investigate the detailed function of the inhibitory recep-
tor for MHC class I in vitro or in vivo, we next investigated 
the physiological role of mouse LILRB2/B3 relatives, PIR-
B, and MHC class I on bone marrow–derived mast cells 
(BMMCs) from C57BL/6 (B6), B2m−/−, or Pirb−/− mice in-
duced by the IL-3–conditioned medium (36). In initial stud-
ies, we confi  rmed comparable expression levels of FcεRI, 
c-Kit, and IL-3 receptor α chain on B2m−/− or Pirb−/− 
BMMCs by fl  ow cytometry (Fig. 3 A). B2m−/− BMMCs also 
showed an expression level of PIR-A/B comparable to that 
of B6 BMMCs (Fig. 3 A), whereas Pirb−/− BMMCs showed 
a very low level of PIR-A expression, indicating a dominant 
expression of PIR-B on mast cells, as previously indicated 
(24, 34). Regarding MHC class I expression, the staining of 
B6 or Pirb−/− BMMCs with H-2Kb/Db mAb yielded com-
parable expression levels of these MHC class I molecules 
(Fig. 3 A). A very low level of H-2Db expression on B2m−/− 
BMMCs detected with anti-H-2Db mAb (Fig. 3 A) may in-
dicate an expression of the H-2 heavy chain dimer, because the 
mAb is able to bind both the canonical H-2 heavy chain/β2m 
heterodimeric structure and the β2m-less heavy chain homo-
dimeric structure  (37, 38).
Because LILRB2 associates with MHC class I on human 
basophilic KU812 cells in cis, we also explored the localiza-
tion of PIRs and MHC class I on mouse mast cells by confo-
cal microscopy. PIR-A/B was colocalized with H-2Db on 
the same cell surface of B6 BMMCs (Fig. 3 B). A weak but 
defi  nite colocalization of PIR-A and MHC class I on Pirb−/− 
Figure 2.  Cis association between LILRB2 and MHC class I on 
KU812 cells. Colocalization of LILRB2 and HLA-A, B, C by FRET analysis 
is shown. From left to right, excited donor (Alexa Fluor 546–conjugated 
LILIRB2 mAb [287219], LILRB3 [222821], and β2m mAb [TÜ99]) images 
(green), excited acceptor (Alexa Fluor 546–conjugated HLA-A, B, C 
[G46-2.6]) images (red), FRET signal images (pseudocolor), and DIC images 
are shown. The cis association between LILRB2 or β2m and HLA-A, B, C 
was determined by FRET. DIC, differential interference contrast.
Table I.  FRET effi  ciency between donor/acceptor pairs bound 
to LILRB2, LILRB3, and β2m on KU812 cells
FRET pairs  FRET effi  ciency (%)a
Donor antibody Acceptor antibody
(Alexa Fluor 546) (Alexa Fluor 647)
LILRB2 HLA-A, B, C 20.7 ± 3
LILRB3 HLA-A, B, C 4 ± 4.9
β2m HLA-A, B, C 14.5 ± 4.7
Energy transfer between different pairs was detected from the increase in 
donor fl  uorescence after acceptor photobleaching. FRET effi  ciency (%) = (1 − 
fl  uorescence intensity of prebleach donor cells/fl  uorescence intensity of postbleach 
donor cells) × 100. FRET effi  ciency >5 was defi  ned as the threshold level for 
substantial transfer effi  ciency.
aData are the mean ± SD (n = 15).JEM VOL. 204, April 16, 2007  911
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Figure 3.  Expression of PIR-A/B and MHC class I on mast cells. 
(A) Flow cytometric analysis of cell-surface expression on BMMCs. After 
a 1-h incubation with anti-TNP–IgE, BMMCs from B6 (black line), Pirb−/− 
(red line), or B2m−/− (blue line) mice were stained with anti–PIR-A/B 
(6C1), anti-IgE (R35-72), anti–c-Kit (2B8), anti–IL-3Rα (5B11), H-2Kb/Db 
(28-8-6), and H-2Db (B22-249.R1). Isotype control stainings (rat IgG1κ 
[R3-34]) or rat IgG2a [R35-95]) are shown (shaded area). (B) Confocal 
imaging of BMMCs. (top) B6, Pirb−/−, or B2m−/− BMMCs were stained 
with Alexa Fluor 488–conjugated anti–PIR-A/B (6C1) and Alexa Fluor 
546–conjugated anti–H-2Db (28-17-8). (bottom) B6 BMMCs were stained 
with Alexa Fluor 488–conjugated SIRP1α (P84) and Alexa Fluor 546–
conjugated anti–H-2Db (28-17-8). DIC, differential interference contrast. 
(C) Relative fl  uorescence intensity of the linearized cell surface in each 
individual cell is shown. (D) Correlation coeffi  cients calculated for the 
colocalization of PIR-A/B, SIRP1α, and H-2Db are shown (n = 15). Data 
are shown as mean ± SD.912  CIS BINDING OF INHIBITORY RECEPTORS TO MHC CLASS I REGULATES ALLERGY | Masuda et al.
BMMCs was also detected (Fig. 3 B). Our fl  uorescent mi-
croscopy failed to detect any robust signal for H-2Db on 
B2m−/− BMMCs (Fig. 3 B). The linearization of the fl  uores-
cence intensity and the σx,y between PIR-B and H-2Db (σx,y = 
0.548 ± 0.15) clearly showed the colocalization between 
PIR-B and H-2Db on the same cell surface (Fig. 3, C and D). 
Moreover, the linearization of the fl  uorescence intensity and 
the σx,y between PIR-A and H-2Db (σx,y = 0.484 ± 0.235) 
also showed the colocalization between PIR-A and H-2Db 
on the same cell surface of Pirb−/− BMMCs (Fig. 3, C and D). 
As a negative control, the fluorescence of signal regula-
tory protein (SIRP) 1α (39), an inhibitory Ig-like receptor 
that recognizes integrin-associated protein CD47, did not 
overlap with that of MHC class I (Fig. 3, B–D). These 
fi  ndings strongly suggest that PIR-A/B can also bind MHC 
class I in cis.
To further confi  rm the cis association between PIR-B 
and MHC class I on BMMCs, we also performed FRET 
analysis with Alexa Fluor 546–conjugated anti–PIR-A/B 
mAb as an energy donor and Alexa Fluor 647–conjugated 
anti–H-2Db mAb as an acceptor (Fig. 4). Table II summarizes 
the FRET effi   ciencies between donor–acceptor pairs bound 
to PIR-A/B, H-2Kb/Db, and SIRP1α. When B6 BMMCs 
were doubly stained with Alexa Fluor 546–conjugated PIR-
A/B mAb (green) and Alexa Fluor 647–conjugated H-2Kb/
Db mAb (red) and excited with the 543-nm laser, we de-
tected a strong FRET eff  ect from the excited PIR-A/B mAb 
signal to the H-2Kb/Db mAb signal (13.5 ± 9.8%; Fig. 4 and 
Table II). A positive control, β2m showed a substantial en-
ergy transfer with H-2Kb/Db (8 ± 3.1%; Fig. 4 and Table II). 
However, we failed to detect any substantial FRET eff  ect 
between PIR-A and H-2Kb/Db on Pirb−/− BMMCs (Fig. 4 
and Table II). A negative control SIRP1α showed no energy 
transfer with H-2Db (Fig. 4 and Table II). These fi  ndings 
demonstrate that PIR-B, as well as LILRB2, can associate 
with MHC class I in cis.
B2m−/− or Pirb−/− BMMCs are hypersensitive 
to IgE or LPS stimulation
Engagement of FcεRI on mast cells with IgE and multivalent 
antigens leads to degranulation and cytokine responses (1–5). 
To clarify whether the association between PIR-B and 
MHC class I physiologically regulates IgE-mediated mast cell 
activation, BMMCs were stimulated with TNP-OVA after 
sensitization with IgE specifi  c for TNP. The degranula-
tion responses were measured by histamine ELISA. Both 
B2m−/− and Pirb−/− BMMCs showed an augmented release 
of histamine compared with B6 BMMCs (Fig. 5 A), indi-
cating a suppressive role of either MHC class I or PIR-B on 
mast cell degranulation. We also examined cytokine and che-
mokine production after cross-linking of FcεRI. Consistent 
with the results of histamine ELISA, both B2m−/− and Pirb−/− 
BMMCs produced more IL-1β, GM-CSF, and macrophage 
infl  ammatory protein (MIP)–1α than B6 BMMCs (Fig. 5 B). 
Figure 4.  Cis association between PIR-B and MHC class I on mast 
cells. Colocalization of PIR-B and H-2Kb/Db by FRET analysis. From left to 
right, excited donor (Alexa Fluor 546–conjugated PIR-A/B mAb [6C1], β2m 
mAb [S19.8], and SIRP1α mAb [P84]) images (green), excited acceptor 
(Alexa Fluor 647–conjugated H-2Kb/Db [28-8-6]) images (red), FRET signal 
images (pseudocolor), and DIC images are shown. The cis association 
between PIR-B or β2m and H-2Kb/Db was determined by FRET. DIC, differ-
ential interference contrast.
Table II.  FRET effi  ciency between donor/acceptor pairs 
bound to PIR-A/B, H-2Kb/Db, and SIRP1α on BMMCs from B6, 
B2m−/−, or Pirb−/− mice
Mice FRET pairs FRET effi  ciency (%)a
Donor antibody Acceptor antibody
(Alexa Fluor 546) (Alexa Fluor 647)
B6 PIR-A/B H-2Kb/Db 13.5 ± 9.8
B2m−/− PIR-A/B H-2Kb/Db n.d.
Pirb−/− PIR-A/B H-2Kb/Db 3.9 ± 3.7
B6 H-2Kb/Db β2m8   ± 3.1
B6 SIRP1α H-2Kb/Db n.d.
Energy transfer between different pairs was detected from the increase in 
donor fl  uorescence after acceptor photobleaching. FRET effi  ciency (%) = (1 − 
fl  uorescence intensity of prebleach donor cells/fl  uorescence intensity of postbleach 
donor cells) × 100. FRET effi  ciency >5 was defi  ned as the threshold level for 
substantial transfer effi  ciency. n.d., not detected (FRET effi  ciency < 0%).
aData are the mean ± SD (n = 15).JEM VOL. 204, April 16, 2007  913
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These results suggested that the interaction between PIR-B 
and MHC class I is physiologically critical to regulate the 
mast cell activation triggered by IgE. On the other hand, 
mast cells express various activating-type receptors other than 
FcεRI. To evaluate whether the deletion of PIR-B or MHC 
class I eff  ects the mast cell activation triggered by other acti-
vating-type receptors, we next investigated cytokine produc-
tion after stimulation with LPS. As shown in Fig. 5 C, both 
B2m−/− and Pirb−/− BMMCs produced more IL-6, GM-
CSF, and MIP-1α than B6 BMMCs. These results suggested 
that the association between PIR-B and MHC class I inhibits 
LPS-mediated mast cell activation and also suggested that 
the PIR-B–MHC class I inhibitory system can maintain the 
activation threshold of the mast cell stimulated with various 
activation-type receptors.
Cis interaction between PIR-B and MHC class I regulates 
mast cell activation
In in vitro culture, mast cells could interact with each other, 
and, thus, PIR-B might also bind MHC class I on surround-
ing mast cells (trans interaction). Therefore, to evaluate 
whether PIR-B associates with MHC class I in cis or trans, or 
both, B2m−/− BMMCs were co-cultured with Pirb−/− or B6 
BMMCs at a 1:1 ratio, because PIR-B on B2m−/− BMMCs 
can interact with MHC class I in trans only. After IgE stimu-
lation, IL-6 production was measured by ELISA. If PIR-B 
binds MHC class I in trans, IL-6 production from B2m−/− 
BMMCs mixed with Pirb−/− or B6 BMMCs would decrease 
because of the inhibitory signaling by PIR-B. Consistent 
with the observation in Fig. 5, both B2m−/− and Pirb−/− 
BMMCs produced more IL-6 than B6 BMMCs (Fig. 6, 
gray-shaded and black-shaded columns vs. open column). In 
particular, Pirb−/− BMMCs produced higher levels of IL-6 
than B2m−/− BMMCs (black-shaded vs. gray-shaded col-
umn). On the other hand, B2m−/− BMMCs mixed with 
Pirb−/− BMMCs produced an almost similar level of IL-6 
compared with Pirb−/− BMMCs alone (diagonally hatched 
column vs. black-shaded column), showing that the cytokine 
production of B2m−/− BMMCs is not aff  ected by the co-
culture with MHC class I–positive mast cells. These results 
indicated that PIR-B on BMMCs predominantly associates 
with MHC class I in cis, thereby regulating mast cell activa-
tion in vitro.
Augmented Fc𝗆RI-mediated signal transduction in B2m−/− 
or Pirb−/− BMMCs
To further investigate the regulatory eff  ect of the cis associa-
tion between PIR-B and MHC class I, FcεRI-mediated 
Figure 5.  Enhanced histamine, cytokine, and chemokine produc-
tion in B2m−/− or Pirb−/− BMMCs stimulated with IgE or LPS. 
(A and B) B6, B2m−/−, or Pirb−/− BMMCs were incubated with TNP-OVA for 
12 h at the indicated concentrations 1h after sensitization with 5 μg/ml 
anti-TNP–IgE. (A) The percentage of histamine release by BMMCs was 
determined by ELISA (n = 3). (B) Concentration of IL-1β, GM-CSF, and 
MIP-1α in the culture media was measured by ELISA (n = 3). (C) B6, 
B2m−/−, or Pirb−/− BMMCs were incubated with LPS for 12 h at the indi-
cated concentrations. Concentrations of IL-6, GM-CSF, and MIP-1α in the 
culture media were measured by ELISA (n = 3). Data are shown as mean ± 
SD of the average of the three different BMMC cultures. Statistical ana-
lyses were performed using the Student’s t test. **, P < 0.01 between 
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  signaling was investigated in either B2m−/− or Pirb−/− 
BMMCs. We fi  rst examined the tyrosine phosphorylation 
status of PIR-B in B6 and B2m−/− BMMCs after stimulation 
with IgE and TNP-OVA. As shown in Fig. 7 A, PIR-B was 
constitutively phosphorylated in B6 BMMCs without any 
stimulation. Upon clustering of FcεRI with IgE and TNP-
OVA, the PIR-B tyrosine phosphorylation immediately 
increased (Fig. 7, A and B). In contrast, the PIR-B phos-
phorylation was signifi  cantly reduced in resting as well as in 
stimulated B2m−/− BMMCs, showing that the absence of cis 
interaction of PIR-B with MHC class I diminished the 
constitutive as well as the induced PIR-B phosphorylation 
(Fig. 7, A and B). Consistent with the reduced phosphoryla-
tion, PIR-B in B2m−/− BMMCs also showed a decreased 
SHP-1 recruitment (Fig. 7, A and B). Concomitant with ei-
ther the reduction of the inhibitory signaling through PIR-B 
in B2m−/− BMMCs or the complete loss of PIR-B–mediated 
inhibition in Pirb−/− cells, FcεRI-mediated phospholipase C 
(PLC)–γ2 phosphorylation was remarkably enhanced (Fig. 7, 
A and B). In addition, the phosphorylation status of FcRγ, 
which associates with FcεRI and PIR-A, was augmented in 
B2m−/− and in Pirb−/− BMMCs (Fig. 7, A and B). The Ca2+ 
mobilization after stimulation with IgE and TNP-OVA was 
also substantially enhanced in B2m−/− as well as in Pirb−/− 
BMMCs (Fig. 7 C). These fi  ndings showed that the PIR-B–
MHC class I interaction in cis is critical for the inhibitory 
signaling against the stimulation through FcεRI.
IgE-dependent passive systemic anaphylaxis is enhanced 
either in B2m−/− or Pirb−/− mice
To verify whether the deletion of PIR-B or MHC class I 
impairs the mast cell activation in vivo, IgE-mediated passive 
systemic anaphylaxis was induced in B2m−/− or Pirb−/− mice. 
This assay refl  ects in vivo IgE-mediated mast cell activation 
(7). Mice were fi  rst intravenously injected with monoclonal 
anti-TNP IgE, followed by a challenge with TNP-OVA 
24 h after injection. After administration with TNP-OVA, 
the rectal temperature was monitored. Upon FcεRI cross-
linking, either B2m−/− or Pirb−/− mice showed a signifi  cant 
decrease in rectal temperature compared with that of B6 mice 
(Fig. 8 A). Histopathological fi   ndings of ear sections also 
showed augmented degranulation of mast cells in either 
B2m−/− or Pirb−/− mice (Fig. 8, B and C). These results 
were consistent with the in vitro studies on mast cells and 
suggested that the PIR-B–MHC class I interaction inhibits in 
vivo mast cell activation. On the other hand, we also induced 
anaphylaxis in FcγRIIB-defi  cient (Fcgr2b−/−) mice under the 
same condition. Fcgr2b−/− mice showed a more severe ana-
phylactic response than Pirb−/− mice (unpublished data), sug-
gesting that FcγRIIB strongly regulates IgE-mediated mast 
cell activation more than other inhibitory receptors, includ-
ing PIR-B, because FcγRIIB can directly bind to IgE as well 
as IgG (40). Finally, to investigate whether PIR-B regulates 
the mast cell activation through the interaction with MHC 
class I in trans in vivo, we induced anaphylaxis in mast cell–
defi  cient WBB6F1-KitW/KitW-v (W/Wv) mice reconstituted 
with B6, B2m−/−, or Pirb−/− BMMCs. However, as shown 
in Fig. 8 D, the passive anaphylaxis was not induced in 
W/Wv mice reconstituted with B2m−/− BMMCs because 
of the failure of the reconstitution (not depicted). It is possi-
ble that other immune cells, such as NK cells, eliminated the 
transferred B2m−/− BMMCs. In contrast, W/Wv mice re-
constituted with Pirb−/− BMMCs showed an augmented 
anaphylactic response compared with W/Wv mice reconsti-
tuted with B6 BMMCs. Thus, further analysis would be 
required to distinguish the contributions of cis and trans 
Figure 6.  PIR-B on BMMCs associates with MHC class I in cis. 
2 × 106 B6, B2m−/−, or Pirb−/− BMMCs were mixed with each other for 
12 h at a 1:1 ratio. Mixed BMMCs were incubated with 10 ng/ml TNP-OVA 
for 12 h after sensitization with 5 μg/ml anti-TNP–IgE. The concentration 
of IL-6 in the culture media was determined by ELISA (n = 3). Data are 
shown as mean ± SD of the average of the three different BMMC 
cultures. (top) Diagrams show the BMMC combination corresponding to 
each column. Statistical analyses were performed using the Student’s 
t test. **, P < 0.01 between the indicated mixed BMMC lines.JEM VOL. 204, April 16, 2007  915
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interactions between PIR-B and MHC class I in vivo. How-
ever, these fi  ndings showed that PIR-B on mast cells regu-
lates allergic reaction in vivo.
D  I  S  C  U  S  S  I  O  N 
The increased incidence of allergic diseases, such as atopic 
dermatitis and bronchial asthma, has become a serious prob-
lem to be urgently solved. Although it is well known that 
combinations of various environmental factors and our ge-
netic elements are related to the development of allergic 
disorders, clarifying the involvement of genetic factors like 
MHC in the development of allergy remains highly com-
plicated (41). Recent basic studies have become especially 
active in the fi  eld of inhibitory receptors that can evoke a 
negative feedback signaling into mast cells (7). On the other 
hand, it is well accepted that MHC class I molecules ex-
pressed ubiquitously are recognized by inhibitory NK re-
ceptors (27, 29). Our previous study, however, showed that 
PIR-B expressed on B cells and myeloid lineage cells can also 
bind MHC class I as its ligand (25). Human PIR-B relatives 
Figure 7.  Augmented intracellular signaling in B2m−/− or Pirb−/− 
BMMCs stimulated with IgE. (A) B6, B2m−/−, or Pirb−/− BMMCs were 
stimulated with 10 ng/ml TNP-OVA at the indicated times 1 h after 
sensitization with 5 μg/ml anti-TNP–IgE. (top) Immunoblots of 
PIR-B phosphotyrosine and PIR-B after the precipitation with p91 antibody 
(sc-9609). (second from top) Immunoblots of PIR-B and SHP-1 after the 
precipitation with SHP-1 antibody (sc-287). (second from bottom) FcRγ 
phosphotyrosine and FcRγ after the precipitation with FcRγ antibody 
(reference 21). (bottom) Antiphosphorylated PLC-γ2 (3871) and PLC-γ2 
(3872) immunoblot analysis. (B) The signal intensity of the indicated pro-
teins in A was estimated by densitometric scanning, normalized by the 
signal intensities of each control protein and represented as a time course 
after IgE stimulation. Each data point is the mean ± SD of three indepen-
dent experiments. The signal intensity of B6 BMMCs at times 0 or 0.5 
was plotted as 1. Statistical analyses were performed using the Student’s 
t test. * (black), P < 0.05; or **, P < 0.01 between B6 and B2m−/− BMMCs. 
* (blue), P < 0.05; or **, P < 0.01 between B2m−/− and B6 BMMCs. * (red), 
P < 0.05; or **, P < 0.01 between Pirb−/− and B6 BMMCs. (C) Ca2+ mobi-
lization in B6, B2m−/−, or Pirb−/− BMMCs. Intracellular free calcium levels 
in Indo-1AM–loaded cells were monitored using an LSR system after cells 
were stimulated with 10 ng/ml TNP-OVA 1 h after sensitization with anti-
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or orthologues, LILRs, are also expressed on myeloid cells 
(14, 42, 43). Particularly, the amino acid sequences of 
LILRB1/B2/B3 and PIR-B show almost similar homologies 
(49.4, 47.3, and 54%, respectively). However, LILRB1 and 
LILRB2 but not LILRB3 bind MHC class I (14). Moreover, 
LILRB1 is not expressed on basophils (13). Thus, in the pre-
sent study, we investigated how an inhibitory MHC class I 
receptor, human LILRB2 or mouse PIR-B, associates with 
MHC class I on human basophils or mouse mast cells, respec-
tively. In addition, although LILRB2 was reported to inhibit 
the basophil activation stimulated with IgE (13), the physio-
logical function of PIR-B in allergic responses remains to be 
clarifi  ed. Therefore, we also examined whether PIR-B has a 
substantial eff  ect on mast cells. Our present observations, in 
which primary Pirb−/− BMMCs stimulated with IgE were 
highly activated, reveal a novel inhibitory role of PIR-B in 
Figure 8.  Augmented IgE-mediated systemic anaphylaxis in 
Pirb−/− or B2m−/− mice. (A) Changes in the rectal temperature of mice 
during IgE-induced systemic anaphylaxis. B6, B2m−/−, or Pirb−/− mice 
intravenously received 1 mg TNP-OVA 24 h after administration with 
anti-TNP–IgE. The monitoring of rectal temperature was started at the 
time of antigen injection. Data are representative of two separate experi-
ments and are expressed as mean ± SD (n = 4). Statistical analyses were 
performed using two-way analysis of variance. * (blue), P < 0.01 between 
B2m−/− and B6 mice. * (red), P < 0.01 between Pirb−/− and B6 mice. 
(B) Ear sections were stained with Toluidine blue 5 min after induction of 
anaphylaxis. Arrows indicate degranulated mast cells. (C) Quantifi  cation 
of degranulated mast cells in tissue sections from ears 5 min after induc-
tion of anaphylaxis. Data are shown as mean ± SD. **, P < 0.01 between 
Pirb−/− or B2m−/− and B6 mice. (D) Mast cell–defi  cient W/Wv mice were 
reconstituted with B6, B2m−/−, or Pirb−/− BMMCs. Systemic anaphylaxis 
was induced in each mice 16 wk after the reconstitution. Data are repre-
sentative of two separate experiments and are expressed as mean ± SD 
(n = 4). Statistical analyses were performed using two-way analysis of 
variance. * (blue), P < 0.01 between W/Wv mice reconstituted with 
B2m−/− and B6 BMMCs. * (red), P < 0.01 between W/Wv mice reconsti-
tuted with Pirb−/− and B6 BMMCs.JEM VOL. 204, April 16, 2007  917
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the mast cell activation. Moreover, we found that B2m−/− 
mice, which lack the expression of PIR-B ligand, MHC 
class I, also showed augmented in vitro and in vivo IgE-
mediated allergic reactions. The FcεRI-mediated signal 
transductions, including Ca2+ infl  ux, were remarkably accel-
erated in either B2m−/− or Pirb−/− BMMCs. These results 
provide a novel insight into how MHC class I itself and its 
inhibitory receptor dampen the cellular activation triggered 
by activating receptors on mast cells.
In the present study, we used FRET analyses to show that 
LILRB2 or PIR-B associate with MHC class I on the same 
cell surface. Particularly, the constitutive cis interaction be-
tween PIR-B and MHC class I could constantly deliver the 
inhibitory signaling into the mast cells. Supporting this no-
tion, PIR-B on B6 BMMCs was phosphorylated without 
any stimulation. In addition, the phosphorylation status of 
PIR-B was down-regulated in B2m−/− BMMCs. These 
fi  ndings indicate that deletion of the cis interaction results in 
a reduction of the constitutive inhibitory signaling through 
PIR-B, thus prompting the augmented eff  ector responses in 
either B2m−/− or Pirb−/− BMMCs. The cis interaction be-
tween an inhibitory MHC class I receptor and MHC class I 
is also observed in NK cells (33). The inhibitory Ly49A NK 
cell receptor, which contains ITIMs in its cytoplasmic por-
tion, not only binds to the H-2Dd ligand expressed on target 
cells (trans interaction) but also interacts with H-2Dd on the 
same cell surface (cis interaction). The cis interaction represses 
the binding capacity of Ly49A to H-2Dd on target cells, lead-
ing to a reduction in the negative signaling mediated by 
Ly49A. Although it remains unclear how the cis or trans in-
teraction aff  ects the inhibitory signaling by Ly49A, it is possi-
ble that the cis interaction dampens the activation threshold 
of NK cells (33, 44). In contrast, the present observation in 
which either B2m−/− or Pirb−/− BMMCs were hypersensi-
tive to IgE stimulation suggests that the PIR-B–MHC class I 
interaction in cis up-regulates the activation threshold of mast 
cells. Our previous study demonstrated that PIR-B binds to 
MHC class I without any allele specifi  city (25). In addition, 
LILRs can recognize various classical and nonclassical MHC 
class I molecules (11, 14, 32, 43). Unlike inhibitory MHC 
class I receptors on NK cells, it is likely that the cis interaction 
between LILRB2 or PIR-B and MHC class I delivers self-
regulatory signaling and maintains an adequate threshold for 
cellular activation.
Our present study of the mixed culture of B2m−/− 
BMMCs with B6 or Pirb−/− BMMCs showed that PIR-B 
associates with MHC class I predominantly in cis but not ap-
preciably in trans. However, we cannot exclude the possible 
occurrence of trans interaction between LILRB2 or PIR-B 
on one cell surface and MHC class I molecules on the other 
cell surface. Rather, it is conceivable that LILRB2 or PIR-B 
can interact with MHC class I both in cis and in trans. In fact, 
the crystal structure of the LILRB1 and HLA-A2 complexes 
suggests that LILRB1 can bind to HLA-A2 in trans (45), ra-
tionalizing a possible trans interaction between MHC class I 
and LILRB2 or PIR-B. Our present analytical system using 
confocal microscopy is only able to depict the cis interactions 
on a KU812 cell or a mast cell. Although further analysis is 
required to unequivocally demonstrate that LILRB2 or PIR-B 
can also bind to MHC class I on other cells in trans, DCs 
that show increased LILRB2/B3 expression can anergize 
alloreactive CD4+ T cells, suggesting the trans interaction 
between LILRB2 and MHC class I (46). In addition, the pre-
sent study did not prove whether PIR-B interacts with MHC 
class I in trans in vivo, because transferred B2m−/− BMMCs 
failed to be reconstituted. However, our previous study al-
ready suggested the possibility of trans interaction between 
PIRs on DCs and MHC class I molecules on allogeneic 
T cells in vivo based on observations in which Pirb−/− DCs 
activated alloreactive CD4+ and CD8+ T cells during the 
induction of graft-versus-host disease (25). Therefore, it is 
reasonable to speculate that mast cells or basophils could also 
recognize MHC class I expressed on surrounding cells in 
the periphery.
Our present data showed that B2m−/− BMMCs mounted 
augmented eff  ector responses as compared with B6 BMMCs. 
However, B2m−/− BMMCs were slightly less sensitive to 
IgE stimulation than Pirb−/− BMMCs. Supporting this fi  nd-
ing, the phosphorylation status of PIR-B was not completely 
diminished in B2m−/− BMMCs. Others also reported a simi-
lar observation in which the level of PIR-B tyrosine phos-
phorylation was reduced by  50% in B2m−/− mice (47). 
Recently, a human misfolded MHC class I, HLA-B27 heavy 
chain dimer was identifi  ed as a novel ligand for both PIR-A 
and PIR-B (48). It has already been reported that the MHC 
class I heavy chain dimer can be expressed on the cell surface 
of mouse B2m−/− cells (37, 38), as was also observed in 
our results (Fig. 3 A). Although we do not exclude the possi-
bility of the presence of other ligands expressed on B2m−/− 
mast cells, PIR-B may bind the MHC class I heavy chain di-
mer on B2m−/− cells, resulting in the slight phosphorylation 
of PIR-B.
In summary, our present study provides evidence that 
LILRB2 or PIR-B associate with MHC class I in cis and, in 
particular, that the cis association between PIR-B and MHC 
class I constitutively delivers negative signaling into mast cells 
and regulates the cellular activation induced by IgE. This in-
hibitory regulation through the cis recognition of “self” could 
be a novel mechanism to maintain adequate cellular responses. 
Indeed, the deletion of PIR-B also renders other immune 
cells, such as neutrophils, macrophages, and DCs, sensitive 
to a variety of activating agents (49, 50).
It is well known that MHC haplotypes relate to the de-
velopment of various immune disorders, including allergy and 
autoimmunity. The inhibitory MHC class I receptors—PIR-B 
in mice and LILRBs in humans—could therefore be potential 
therapeutic targets that overcome MHC haplotype variations.
MATERIALS AND METHODS
Mice. C57BL/6 (B6) mice were purchased from Charles River Labora-
tories. B2m−/− mice were purchased from the Jackson Laboratory. Mast 
cell–defi  cient WBB6F1-KitW/KitW-v (W/Wv) mice were purchased from 
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were backcrossed onto B6 for 12 generations. Mice were kept and bred in 
the Animal Unit of the Institute of Development, Aging and Cancer (IDAC) 
at Tohoku University, an environmentally controlled and specifi  c pathogen-
free facility, according to the guidelines for experimental animals defi  ned by 
the facility. Animal protocols were reviewed and approved by the IDAC 
Animal Studies Committee. All experiments were performed on 8–12-wk-
old age-matched mice.
Flow cytometry. KU812 cells, a human early basophilic leukocyte cell 
line, were donated by M. Numazaki (Tohoku University, Sendai-shi, 
Japan), and are cultured in T25 tissue culture fl  asks under IL-4–conditioned 
medium (51, 52). BMMCs were prepared as previously described (36). For 
fl  ow cytometric analysis of KU812 cells, the following human-specifi  c mAbs 
were used: anti-FcεRI (CRA1; Kyokuto Pharmaceutical Indust. Co. Ltd.), 
biotinylated mouse IgG2b (MPC-11; BD Biosciences), anti-LILRB1 
(GHI/75; BD Biosciences), anti-LILRB2 (287219; R&D Systems), anti-
LILRB3 (222821; R&D Systems), PC5-conjugated anti-LILRB4 (ZM3.8; 
Beckman Coulter), PC5-conjugated mouse IgG1 (679.1Mc7; Beckman 
Coulter), anti–HLA-A, B, C (G46-2.6), anti-β2m (TÜ99; BD Biosciences), 
and biotinylated mouse IgM (G155-228; BD Biosciences). The nonlabeled 
mAbs were biotinylated by using reagents (EZ-Link Sulfo-NHS-Biotin; 
Pierce Chemical Co.) and labeled with streptavidin–Alexa Fluor 546 (Invit-
rogen). For fl  ow cytometric analysis of BMMCs, the following mouse-
specifi  c mAbs were used: FITC- or PE-conjugated anti–c-Kit (2B8), anti-IgE 
(R35-72), anti–IL-3α (5B11), anti–H-2Db (28-17-8), anti–H-2Kb/Db (28-
8-6), anti–PIR-A/B (6C1), rat IgG1k (R3-34), rat IgG2a (R35-95), and 
anti-SIRP1α (P84). These antibodies were all purchased from BD Bio-
sciences. For the detection of MHC class I heavy chain dimer, anti–mouse 
H-2Db (B22-249.R1; Cedarlane Laboratories Ltd.) labeled with Alexa Fluor 
546 was used (37, 38). Cell surfaces were stained using standard techniques, 
and fl  ow cytometric analysis was performed using a FACS LSR and Cell-
Quest software (both from BD Biosciences).
Confocal microscopy analysis. Confocal laser scanning microscopy of 
KU812 cells was performed with Alexa Fluor 546–conjugated anti-LILRB2 
(287219), LILRB3 (222821), anti-β2m (TÜ99), and Alexa Fluor 647–
conjugated anti–HLA-A, B, C (G46-2.6). Confocal laser scanning microscopy 
of BMMCs was performed with Alexa Fluor 488, 546, or 594–conjugated 
(all from Invitrogen) anti–PIR-A/B (6C1; a gift from H. Kubagawa and 
M.D. Cooper, University of Alabama at Birmingham, Birmingham, AL), 
anti–H-2Kb/Db (28-8-6), anti–mouse β2m (S19.8; BD Biosciences), and 
anti–SHPS-1 mAbs (BD Biosciences) after fi  xing with 4% paraformalde-
hyde. All of these mAbs were directly labeled by an Alexa Fluor 488, 546, or 
647 monoclonal labeling kit (Invitrogen). Alexa Fluor 488, 546, or 594–
positive signals were collected by a confocal laser scanning microscope 
(Fluoview FV1000; Olympus).
Linearization analysis and the calculation of correlation coeffi   cient. 
Linearization analysis determines the location of the receptors observed in 
one plane of the cell versus the entire cell. Scans of the cell surface were 
made by drawing a ring-shaped area at the mid focal plane of each cell. The 
fl  uorescence intensity of the two target molecules was normalized relative to 
the highest peak (y axis). The correlation coeffi   cient was calculated on a 
pixel-by-pixel basis according to
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where x and y are the intensities of the green and red channels in a pixel, and 
x and y are the average intensities of the green and red channels within the 
region of interest. The correlation coeffi   cient theoretically ranges from −1 
to 1, where 1 indicates perfect overlap, 0 indicates random distribution, and 
−1 indicates avoidance.
FRET analysis and image processing. KU812 cells or BMMCs plated 
on poly–l-lysine–coated glass-bottom dishes (Matsunami Glass Ind. Ltd.) 
were imaged with a Fluoview FV1000 confocal microscopy equipped with 
three photomultipliers (PMTs), a heated-stage CO2 chamber system, and 
an objective heater (Olympus) and controlled by FV-10ASW software 
(Olympus). All imaging of living cells was done at 37°C. An oil-immersion 
objective (PlanApoN 60; Olympus) was used exclusively for image acquisition. 
Alexa Fluor 546/647 FRET imaging was performed with sequential ex-
citation at 543 nm and collection of donor–Alexa Fluor 546 (excitation = 
555 nm; emission = 625 nm) and FRET (>650 nm) emission, followed 
by a 633-nm excitation and acceptor–Alexa Fluor 647 (>650 nm) detection. 
Settings were kept unchanged for analysis of all samples. Unless otherwise 
indicated in the fi  gure legends, donor emission was detected on the PMT2, 
and acceptor and FRET emissions were recorded on the PMT3. To deter-
mine the donor and acceptor spectral bleed throughs in the FRET setting, 
individual donor- or acceptor-stained samples were also imaged. After image 
acquisition, FRET images were calculated using FV-10ASW software and 
ImageJ software (National Institutes of Health) with the plug-in program 
PixFRET (available at http://www.unil.ch/cig/page16989.html) (53). The 
calculated FRET effi   ciency (E) was as follows: E = 1 − IDA/ID, where IDA 
indicates the fl  uorescence intensity of prebleach donor cells and ID indicates 
the fl  uorescence intensity of postbleach donor cells. E > 0.05 was defi  ned as 
the threshold level for substantial transfer effi   ciency.
Histamine and cytokine ELISA. 2 × 106 BMMCs/well were cultured in 
96-well fl   at plates (BD Biosciences). The supernatants of 12-h cultured 
BMMCs stimulated with TNP-OVA 1 h after sensitization with 5 μg/ml 
anti-TNP–IgE (C38-2; BD Biosciences) or LPS (Sigma-Aldrich) were col-
lected and kept frozen at −80°C. The amount of cytokine production was 
determined by a Multiplex suspension array system (Bio-Rad Laboratories) 
for MIP-1α, GM-CSF, IL-1β, and IL-6. For histamine release, histamine 
in the supernatant and cellular pellet fractions was measured by ELISA 
(Neogen Corporation). The percentage of histamine release was quantitated 
by the following equation: histamine in supernatant/(histamine in superna-
tant + histamine in pellet) × 100. For the co-culture experiment, 4 × 106 
mixed BMMCs/well were cultured in 96-well round plates (BD Biosci-
ences) for 12 h. IL-6 concentration in the supernatant of 12-h cultured 
BMMCs was stimulated with TNP-OVA 1 h after the sensitization with 5 
μg/ml anti-TNP–IgE (C38-2; BD Biosciences) and measured by ELISA 
(BioLegend, Inc.).
Immunoblot and immunoprecipitation analysis. 2 × 106 BMMCs 
in 1 ml PBS were stimulated for 0 s, 30 s, 2 min, and 30 min at 37°C with 
10 ng/ml TNP 1 h after incubation with 5 μg/ml anti-TNP–IgE. Cells were 
solubilized in a lysis buff  er (0.75% Briji-97 [Sigma-Aldrich], 150 mM Hepes 
[pH 7.4], and 50 mM NaCl) containing 2 mM sodium vanadate (Sigma-
Aldrich) and supplemented with proteinase inhibitors (Sigma-Aldrich). For 
immunoblot analysis, cell lysates were separated by SDS–PAGE gel, trans-
ferred to a polyvinylidene difl  uoride membrane, and detected by antiphos-
phorylated PLC-γ2 (3871; Cell Signaling Technology, Inc.) and horseradish 
peroxidase (HRP)–goat anti–rabbit IgG (GE Healthcare). For immunopre-
cipitation analysis, precleared lysates were sequentially incubated with anti-
p91 (sc-9609; Santa Cruz Biotechnology Inc.), anti–SHP-1 (sc-287; Santa 
Cruz Biotechnology Inc.), or rabbit anti-FcR common γ (polyclonal rabbit 
IgG) (21) and protein G–conjugated sepharose 4B (GE Healthcare). The 
immunoprecipitates were separated by SDS-PAGE gel, transferred to a poly-
vinylidene difl  uoride membrane, and detected by HRP-antiphosphotyro-
sine mAb (4G10; Upstate Biotechnology) with the electrochemiluminescence 
system (GE Healthcare). The detected membranes were stripped off   with a 
stripping buff  er that contained 62.5 mM Tris (pH 6.8), 100 mM 2-mercap-
toethanol, and 2% SDS and reblotted with the appropriate antibodies. These 
were anti–PLC-γ2 (3872; Cell Signaling Technology, Inc.), anti-p91, anti–
SHP-1, or anti-FcRγ and HRP–goat anti–rabbit IgG (GE Healthcare).
Measurement of intracellular calcium. BMMCs were resuspended to 
107 cells/ml in RPMI 1640 containing 1% FBS 1 h after incubation with 
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added at a fi  nal concentration of 5 mM, and the cells were incubated for a 
further 30 min. The cells were centrifuged and resuspended in RPMI 1640 
at 106 cells/ml. The cells were stimulated with 10 ng/ml TNP-OVA, and 
the fl  uorescence intensity of intracellular Indo-1AM was monitored and an-
alyzed using an LSR system.
Induction of passive systemic anaphylaxis. Mouse IgE anti-TNP mAbs 
(C38-2) were administered intravenously through the tail vein in a volume 
of 200 μl per mouse. Mice were injected intravenously with 1 mg TNP-
OVA in PBS 24 h after the injection of IgE (20 μg per mouse). Changes in 
the core body temperature associated with systemic anaphylaxis were moni-
tored by measuring changes in rectal temperature using a rectal probe cou-
pled to a digital thermometer (Natsume Seisakusyo). For the reconstitution 
of BMMCs in W/Wv mice, 5× 106 BMMCs in 100 μl were injected intra-
venously through the tail vein into W/Wv mice. Mice were housed for 
16 wk before the induction of anaphylaxis.
Histological study. Mice were killed by cervical dislocation. Their tissues 
were removed and fi  xed in 10% (vol/vol) neutral-buff  ered formalin and 
embedded in paraffi   n. The specimens were sectioned at 3 μm and stained 
with toluidine blue (pH 4). For evaluation of degranulated mast cells, seven 
high power fi  elds (40× objective) of each ear were examined on a micro-
scope (BX50; Olympus).
Statistical analysis. Statistical diff  erences were calculated using the Student’s 
t test or two-way analysis of variance. P < 0.05 was considered signifi  cant.
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